MK 3475-689

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

01.04.2018 bis 29.02.2024

Pembrolizumab as neoadjuvant therapy and in combinations with standard of care (SoC) radiotherapy (RT) with/without cisplatin as adjuvant therapy is being investigated for participants with newly diagnosed Stage III/IV (IVA/IVB), resectable, locoregionally advanced head and neck squamous cell cancers (LA HNSCC). Its efficacy and safety are being evaluated against SoC treatment in this randomized, open-label, Phase III study.